233O - Time to deterioration of symptoms with durvalumab in stage III, locally advanced, unresectable NSCLC: Post-hoc analysis of PACIFIC patient-reported...

Date 13 April 2018
Event ELCC 2018 European Lung Cancer Congress
Session ESMO-IASLC Best Abstracts
Topics Non-Small-Cell Lung Cancer, Metastatic
Cancer Immunology and Immunotherapy
Lung and other Thoracic Tumours
Presenter Scott Antonia
Citation Journal of Thoracic Oncology (2018) 13 (supp_4): S1-S139.
Authors R. Hui1, M. Özgüroğlu2, A. Villegas3, D. Daniel4, D. Vicente Baz5, S. Murakami6, A. Rydén7, Y. Zhang7, P. Dennis8, S.J. Antonia9
  • 1Westmead Hospital, 2145 - Sydney/AU
  • 2Cerrahpasa Faculty Of Medicine, Division Of Medical Oncology, Istanbul University, Istanbul/TR
  • 3Florida Cancer Specialists, 000 - Tampa/US
  • 4Tennessee Oncology, TN - Chattanooga/US
  • 5Hospital Universitario Virgen Macarena, 41003 - Sevilla/ES
  • 6Thoracic Oncology, National Cancer Center Research Institiute, 104-0045 - Tokyo/JP
  • 7AstraZeneca, Gaithersburg/US
  • 8AstraZeneca, MD 20878 - Gaithersburg/US
  • 9Thoracic Oncology, H. Lee Moffitt Cancer Center University of South Florida, 33612 - Tampa/US


Along with improving efficacy outcomes such as progression-free survival (PFS) after concurrent chemoradiotherapy (cCRT) in locally advanced, unresectable NSCLC, it is critical that new therapies are well tolerated in the curative intent setting. We studied the impact of 12 mo of durvalumab on disease symptoms in this setting using patient-reported outcomes (PROs). In a post-hoc analysis of time to deterioration, we adjusted for transient symptom changes by requiring two consecutive deterioration recordings.